𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positivechronic hepatitis B

✍ Scribed by Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori…

Book ID
120914439
Publisher
Springer Japan
Year
2012
Tongue
English
Weight
376 KB
Volume
48
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term outcomes of thymosin-α1 and in
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Entecavir treatment for up to 5 years in
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B
✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E